Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00025727
Status:
UNKNOWN
Last Update Posted:
2005-06-24
First Post:
2001-10-15
Brief Title:
Comparison of Two Dosing Regimens of GW433908Ritonavir Versus LopinavirRitonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
Sponsor:
GlaxoSmithKline
Organization:
NIH AIDS Clinical Trials Information Service
Study Overview
Official Title:
A Phase III Randomized Multicenter Parallel Group Open-Label Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908Ritonavir 700mg100mg Twice Daily or 1400mg200mg Once Daily Versus LopinavirRitonavir 400mg100mg Twice Daily for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure
Status:
UNKNOWN
Status Verified Date:
2002-06
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to test 2 different dosing regimens of GW433908ritonavir RTV versus lopinavir LPVRTV when each is given with 2 active reverse transcriptase inhibitors RTIs in patients who have taken anti-HIV drugs without success
Detailed Description:
Patients will receive 2 dosing regimens of GW433908RTV or LPVRTV in combination with 2 active RTIs after failing their first or second protease inhibitor-containing regimen Patients are required to be on therapy at time of screening and must remain on this therapy until Day 1
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: